US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NewcelX Ltd.

2.90

-0.1350-4.45%

Volume:2K

Turnover:6.34K

Market Cap:16.75M

PE:-5.69

High:2.93

Open:2.93

Low:2.89

Close:3.04

52wk High:19.07

52wk Low:1.83

Shares:5.78M

Float Shares:2.68M

Volume Ratio:1.55

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5097

EPS(LYR):-2.1592

ROE:--

ROA:-49.59%

PB:2.77

PE(LYR):-1.34

Loading ...

Overview Company News Filings

NewcelX Management Attends Breakthrough T1D Clinical & Research Congress

NewcelX FY26 H1 Net Loss Attributable to Common Shareholders Narrows 50% to USD 5.63 Million

NewcelX Prices Private Placement with 347,134 Share Warrants at $4.44 Exercise Price

NewcelX Prices USD 1.4 Million Private Placement at USD 4.03 Per Share

Newcelx Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

THOMSON REUTERS

Press Release: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

NewcelX Obtains Patent in Brazil for Potential Type 1 Diabetes Treatment

MT Newswires Live

NewcelX announces Brazil patent for cell selection, enrichment technology

Newcelx Ag - Granted Brazilian Patent for Ncel-101 Manufacturing Process Until November 2036

THOMSON REUTERS

Newcelx Wins Brazil Patent for Ncel-101 Manufacturing Process Through 2036

Newcelx Initiated at Buy by Laidlaw & Co.

NewcelX initiated with a Buy at Laidlaw

Newcelx Appoints World-renowned Diabetes Cure-focused Pioneer, DR. Camillo Ricordi, to Scientific Advisory Board

THOMSON REUTERS

Press Release: Newcelx Appoints World-renowned Diabetes Cure-focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

Newcelx Reports Successful FDA Pre-ind Meeting for Ncel-101 Type 1 Diabetes Trial Plan

NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101

Newcelx Announces Successful FDA Pre-ind Meeting with Clear Path Forward for Ncel-101 Toward Starting Clinical Trials for Type 1 Diabetes

THOMSON REUTERS

Newcelx Ag - FDA Approves Newcelx to Proceed with Ind-enabling Activities for Ncel-101

THOMSON REUTERS

Newcelx Holds Annual General Shareholders Meeting

NewcelX reports Stem Cell Reports study shows AstroRx cell therapy boosts remyelination in MS models

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/NCEL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","market":"US","secType":"STK","nameCN":"NewcelX Ltd.","latestPrice":2.9,"timestamp":1791473905523,"preClose":3.035,"halted":0,"volume":2175,"delay":0,"changeRate":-0.044481054365733186,"floatShares":2683800,"shares":5776100,"eps":-0.509695,"marketStatus":"Trading","change":-0.135,"latestTime":"10-08 11:40:47 EDT","open":2.925,"high":2.925,"low":2.89,"amount":6343.0123125,"amplitude":0.011532,"askPrice":3.03,"askSize":81,"bidPrice":2.81,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.509695,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"listingDate":1611896400000,"exchange":"NASDAQ","adjPreClose":3.035,"postHourTrading":{"tag":"盘后","latestPrice":3.035,"preClose":3.035,"latestTime":"19:30 EDT","volume":6,"amount":17.6,"timestamp":1791415800816,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.547534},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","floatShares":2683800,"roa":"-49.59%","roe":"--","lyrEps":-2.159218,"volumeRatio":1.547534,"shares":5776100,"dividePrice":0,"high":2.925,"amplitude":0.011532,"preClose":3.035,"low":2.89,"week52Low":1.8299,"pbRate":"2.77","week52High":19.067,"institutionHeld":0,"latestPrice":2.9,"committee":0.423488,"eps":-0.509695,"divideRate":0,"volume":2175,"delay":0,"ttmEps":-0.509695,"open":2.925,"prevYearClose":1.9,"prevWeekClose":2.85,"prevMonthClose":3.075,"prevQuarterClose":3.075,"fiveDayClose":2.91,"twentyDayClose":3.38,"sixtyDayClose":3.93},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-04-30","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1777521600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-10-31","symbol":"NCEL","defaultRemindTime":1761917400000,"type":"split","dateTimestamp":1761883200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-05-16","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1747368000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-09-27","symbol":"NCEL","defaultRemindTime":1727443800000,"type":"split","dateTimestamp":1727409600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCEL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1784001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCEL","date":"2026-10-07","current":-5.954541,"percent":0.978355,"low":-2.743828,"twenty":-2.257334,"median":-0.838689,"eighty":-0.570623,"high":330.8146,"avg":16.100282,"sd":71.690049,"marketCap":17101382},"quantilePoints":[{"date":"2025-10-31","current":-2.085416,"twenty":-2.085416,"median":-2.085416,"eighty":-2.085416,"marketCap":39937082.48},{"date":"2025-11-07","current":-0.993097,"twenty":-1.495376,"median":-1.229626,"eighty":-1.098389,"marketCap":18917268},{"date":"2025-11-14","current":-0.808829,"twenty":-1.253274,"median":-0.970727,"eighty":-0.876223,"marketCap":15635236},{"date":"2025-11-21","current":-0.750891,"twenty":-1.145695,"median":-0.878334,"eighty":-0.814355,"marketCap":14358890},{"date":"2025-11-28","current":-0.957951,"twenty":-1.045743,"median":-0.867781,"eighty":-0.806793,"marketCap":18279095},{"date":"2025-12-05","current":-0.856292,"twenty":-0.972009,"median":-0.871696,"eighty":-0.812974,"marketCap":16455744},{"date":"2025-12-12","current":-0.781666,"twenty":-0.995845,"median":-0.875612,"eighty":-0.812974,"marketCap":15179398},{"date":"2025-12-19","current":-0.635834,"twenty":-0.972009,"median":-0.85736,"eighty":-0.781019,"marketCap":12353204},{"date":"2025-12-26","current":-0.613233,"twenty":-0.957493,"median":-0.83848,"eighty":-0.693066,"marketCap":11988534},{"date":"2026-01-02","current":-0.442896,"twenty":-0.955117,"median":-0.833152,"eighty":-0.615876,"marketCap":8660918},{"date":"2026-01-09","current":-0.513637,"twenty":-0.941907,"median":-0.808829,"eighty":-0.589968,"marketCap":10074015},{"date":"2026-01-16","current":-0.561129,"twenty":-0.915578,"median":-0.78535,"eighty":-0.566624,"marketCap":11122442},{"date":"2026-01-23","current":-0.610165,"twenty":-0.913462,"median":-0.76547,"eighty":-0.561129,"marketCap":12125285},{"date":"2026-01-30","current":-0.576613,"twenty":-0.882218,"median":-0.6841,"eighty":-0.565731,"marketCap":11623863},{"date":"2026-02-06","current":-0.601541,"twenty":-0.878334,"median":-0.628521,"eighty":-0.570197,"marketCap":12034117},{"date":"2026-02-13","current":-0.627168,"twenty":-0.875612,"median":-0.627168,"eighty":-0.572325,"marketCap":12717874},{"date":"2026-02-20","current":-0.632256,"twenty":-0.869347,"median":-0.627168,"eighty":-0.573006,"marketCap":12581123},{"date":"2026-02-27","current":-0.656951,"twenty":-0.860299,"median":-0.626808,"eighty":-0.575926,"marketCap":13082544},{"date":"2026-03-06","current":-0.638142,"twenty":-0.856719,"median":-0.630594,"eighty":-0.581513,"marketCap":12854625},{"date":"2026-03-13","current":-0.639458,"twenty":-0.843011,"median":-0.628376,"eighty":-0.587749,"marketCap":12717874},{"date":"2026-03-20","current":-0.559522,"twenty":-0.837754,"median":-0.626853,"eighty":-0.587749,"marketCap":11168026},{"date":"2026-03-27","current":-0.565498,"twenty":-0.835865,"median":-0.623182,"eighty":-0.571899,"marketCap":11259193},{"date":"2026-04-02","current":-0.537802,"twenty":-0.83268,"median":-0.620613,"eighty":-0.56375,"marketCap":10712188},{"date":"2026-04-10","current":-0.468376,"twenty":-0.821759,"median":-0.618412,"eighty":-0.555851,"marketCap":9527010},{"date":"2026-04-17","current":-0.546102,"twenty":-0.811592,"median":-0.616697,"eighty":-0.55169,"marketCap":11350361},{"date":"2026-04-24","current":-1.072253,"twenty":-0.811592,"median":-0.617492,"eighty":-0.552903,"marketCap":22381635},{"date":"2026-05-01","current":-0.95322,"twenty":-0.83268,"median":-0.620255,"eighty":-0.55452,"marketCap":20102446},{"date":"2026-05-08","current":-1.779415,"twenty":-0.838489,"median":-0.62112,"eighty":-0.555851,"marketCap":14769144},{"date":"2026-05-15","current":-2.224901,"twenty":-0.870913,"median":-0.625846,"eighty":-0.556353,"marketCap":18466677},{"date":"2026-05-22","current":-2.062736,"twenty":-0.91452,"median":-0.627168,"eighty":-0.558257,"marketCap":17120709},{"date":"2026-05-29","current":-2.296253,"twenty":-0.955372,"median":-0.628812,"eighty":-0.55988,"marketCap":19058903},{"date":"2026-06-05","current":-2.043276,"twenty":-1.009476,"median":-0.634045,"eighty":-0.560702,"marketCap":16959193},{"date":"2026-06-12","current":-2.118586,"twenty":-1.18766,"median":-0.639458,"eighty":-0.562877,"marketCap":17584261},{"date":"2026-06-18","current":-2.043276,"twenty":-1.814564,"median":-0.642142,"eighty":-0.565545,"marketCap":16959193},{"date":"2026-06-26","current":-2.30274,"twenty":-1.957423,"median":-0.652667,"eighty":-0.566624,"marketCap":19112742},{"date":"2026-07-02","current":-2.497338,"twenty":-2.043276,"median":-0.658096,"eighty":-0.570197,"marketCap":20727903},{"date":"2026-07-10","current":-2.678962,"twenty":-2.05625,"median":-0.697542,"eighty":-0.572325,"marketCap":22235387},{"date":"2026-07-17","current":-2.536257,"twenty":-2.075709,"median":-0.73457,"eighty":-0.573176,"marketCap":21050935},{"date":"2026-07-24","current":-2.464905,"twenty":-2.085416,"median":-0.750891,"eighty":-0.576613,"marketCap":20458709},{"date":"2026-07-31","current":-2.180403,"twenty":-2.102953,"median":-0.781666,"eighty":-0.580006,"marketCap":18097343},{"date":"2026-08-07","current":-2.166522,"twenty":-2.154845,"median":-0.801508,"eighty":-0.582361,"marketCap":17982129},{"date":"2026-08-14","current":-2.335173,"twenty":-2.160035,"median":-0.815737,"eighty":-0.587749,"marketCap":19381935},{"date":"2026-08-21","current":-2.185981,"twenty":-2.167171,"median":-0.833563,"eighty":-0.589629,"marketCap":18143645},{"date":"2026-08-28","current":-2.380043,"twenty":-2.188576,"median":-0.837687,"eighty":-0.590513,"marketCap":19754357},{"date":"2026-09-04","current":-2.331329,"twenty":-2.227496,"median":-0.85736,"eighty":-0.590877,"marketCap":19350028},{"date":"2026-09-11","current":-2.352206,"twenty":-2.24955,"median":-0.871696,"eighty":-0.593951,"marketCap":19523312},{"date":"2026-09-18","current":-2.352206,"twenty":-2.26257,"median":-0.882218,"eighty":-0.596565,"marketCap":19523312},{"date":"2026-09-25","current":303.509255,"twenty":-2.261737,"median":-0.871696,"eighty":-0.589472,"marketCap":16693009},{"date":"2026-10-02","current":305.609673,"twenty":-2.259095,"median":-0.856292,"eighty":-0.575238,"marketCap":16808532},{"date":"2026-10-07","current":310.934218,"twenty":-2.257334,"median":-0.838689,"eighty":-0.570623,"marketCap":17101382}],"updateTime":1791455990639},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCEL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670628232","title":"NewcelX Management Attends Breakthrough T1D Clinical & Research Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2670628232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670628232?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:06","pubTimestamp":1790597179,"startTime":"0","endTime":"0","summary":"NewcelX management attends Breakthrough T1D Clinical & Research CongressNewcelX management will attend the Breakthrough T1D Clinical & Research Congress in Philadelphia on Oct. 9-11, 2026.Meetings pla","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL3vbRcN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973316","title":"NewcelX FY26 H1 Net Loss Attributable to Common Shareholders Narrows 50% to USD 5.63 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973316","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973316?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:16","pubTimestamp":1789762578,"startTime":"0","endTime":"0","summary":"NewcelX FY26 H1 net loss attributable to common shareholders narrows 50% to USD 5.63 millionNewcelX posted a net loss attributable to common shareholders of USD 5.63 million for the six months ended J","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL24lBn1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655361815","title":"NewcelX Prices Private Placement with 347,134 Share Warrants at $4.44 Exercise Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2655361815","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655361815?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:11","pubTimestamp":1785503506,"startTime":"0","endTime":"0","summary":"NewcelX prices private placement with 347,134 share warrants at $4.44 exercise priceNewcelX priced a private placement that includes one series of warrants to buy 347,134 common shares at an exercise price of $4.44.The warrants were issued alongside 347,134 common shares sold at $4.03 per share; the deal is expected to close around Aug. 14.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 31, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL5cchF4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655369246","title":"NewcelX Prices USD 1.4 Million Private Placement at USD 4.03 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2655369246","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655369246?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:00","pubTimestamp":1785502836,"startTime":"0","endTime":"0","summary":"NewcelX prices USD 1.4 million private placement at USD 4.03 per shareNewcelX priced a USD 1.4 million private placement at USD 4.03 per share, a 20% premium to the July 30 close.Deal covers 347,134 c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL9Dppng:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4588","BK4139","BK4112","BCDF","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00BGHQF748.EUR","BK4585","SG9999014005.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","ELDN","NDAQ","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","NCEL","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655369259","title":"Newcelx Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2655369259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655369259?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:00","pubTimestamp":1785502800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUAQBBJN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655697433","title":"Press Release: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2655697433","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655697433?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:00","pubTimestamp":1785502800,"startTime":"0","endTime":"0","summary":"ZURICH, Switzerland, July 31, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for type 1 diabetes, today announced","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4215","BK4588","BK4139","REZ","NCEL","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651466637","title":"NewcelX Obtains Patent in Brazil for Potential Type 1 Diabetes Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2651466637","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651466637?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:20","pubTimestamp":1784121654,"startTime":"0","endTime":"0","summary":"NewcelX  has obtained a patent from the Brazilian Patent and Trademark Office protecting the manufacturing process of its lead clinical compound, NCEL-101, the company said Wednesday.The patent, which covers its cell selection and enrichment technology, is valid until November 2036, the company said.NewcelX said it recently completed a type B pre-Investigation New Drug meeting with the US Food and Drug Administration, regarding the drug, which is targeted at treating type 1 diabetes in combination with Eledon's anti-CD40L monoclonal antibody.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NCEL","EWZS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651665274","title":"NewcelX  announces Brazil patent for cell selection, enrichment technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2651665274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651665274?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:15","pubTimestamp":1784121348,"startTime":"0","endTime":"0","summary":"NewcelX (NCEL)announced that the Brazilian Patent and Trademark Office has issued a patent covering its cell selection and enrichment technology. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/newcelx-announces-brazil-patent-for-cell-selection-enrichment-technology-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/newcelx-announces-brazil-patent-for-cell-selection-enrichment-technology-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWZS","NCEL","USRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651465260","title":"Newcelx Ag - Granted Brazilian Patent for Ncel-101 Manufacturing Process Until November 2036","url":"https://stock-news.laohu8.com/highlight/detail?id=2651465260","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651465260?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:07","pubTimestamp":1784120868,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H1BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651173465","title":"Newcelx Wins Brazil Patent for Ncel-101 Manufacturing Process Through 2036","url":"https://stock-news.laohu8.com/highlight/detail?id=2651173465","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651173465?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:03","pubTimestamp":1784120622,"startTime":"0","endTime":"0","summary":"NewcelX wins Brazil patent for NCEL-101 manufacturing process through 2036NewcelX received a Brazilian patent covering its cell selection and enrichment manufacturing process for NCEL-101 in type 1 di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL1KbNMg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","BK4139","NCEL","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651116735","title":"Newcelx Initiated at Buy by Laidlaw & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2651116735","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651116735?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:38","pubTimestamp":1783942680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NCEL/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 07:38 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651192033","title":"NewcelX  initiated with a Buy at Laidlaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2651192033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651192033?lang=en_us&edition=fundamental","pubTime":"2026-07-13 17:00","pubTimestamp":1783933213,"startTime":"0","endTime":"0","summary":"Laidlaw initiated coverage of NewcelX (NCEL) with a Buy rating and $23 price target NewcelX is an early clinical stage biotech company focusing on ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/newcelx-initiated-with-a-buy-at-laidlaw-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/newcelx-initiated-with-a-buy-at-laidlaw-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649999872","title":"Newcelx Appoints World-renowned Diabetes Cure-focused Pioneer, DR. Camillo Ricordi, to Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2649999872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649999872?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:15","pubTimestamp":1783516500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nTUABYNVMB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649999352","title":"Press Release: Newcelx Appoints World-renowned Diabetes Cure-focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2649999352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649999352?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:15","pubTimestamp":1783516500,"startTime":"0","endTime":"0","summary":"The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trialsDr. Ricordi to support advancement o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245756.USD","BK4209","DRI","NCEL","BK4585","BK4139","LU0154245673.USD","BK4504","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648687647","title":"Newcelx Reports Successful FDA Pre-ind Meeting for Ncel-101 Type 1 Diabetes Trial Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2648687647","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648687647?lang=en_us&edition=fundamental","pubTime":"2026-07-03 02:32","pubTimestamp":1783017158,"startTime":"0","endTime":"0","summary":"NewcelX reports successful FDA pre-IND meeting for NCEL-101 type 1 diabetes trial planNewcelX reported a successful FDA Type B pre-IND meeting for NCEL-101 in type 1 diabetes, outlining a clear path t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDLJ4mrf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648546132","title":"NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2648546132","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648546132?lang=en_us&edition=fundamental","pubTime":"2026-07-01 21:35","pubTimestamp":1782912915,"startTime":"0","endTime":"0","summary":"NewcelX (NCEL) announced the completion of its Type B Pre-IND meeting with the U.S. Food and Drug Administration. The agency provided constructive ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/newcelx-completes-type-b-pre-ind-meeting-with-fda-for-ncel-101-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/newcelx-completes-type-b-pre-ind-meeting-with-fda-for-ncel-101-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","IND","NCEL","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648546386","title":"Newcelx Announces Successful FDA Pre-ind Meeting with Clear Path Forward for Ncel-101 Toward Starting Clinical Trials for Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2648546386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648546386?lang=en_us&edition=fundamental","pubTime":"2026-07-01 21:30","pubTimestamp":1782912600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nTUA1NPMBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648463395","title":"Newcelx Ag - FDA Approves Newcelx to Proceed with Ind-enabling Activities for Ncel-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2648463395","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648463395?lang=en_us&edition=fundamental","pubTime":"2026-07-01 21:30","pubTimestamp":1782912600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nTUA1NPMBM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648564259","title":"Newcelx Holds Annual General Shareholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2648564259","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648564259?lang=en_us&edition=fundamental","pubTime":"2026-07-01 04:31","pubTimestamp":1782851488,"startTime":"0","endTime":"0","summary":"NewcelX holds annual general shareholders meetingNewcelX AG held its annual general shareholders’ meeting on June 30, 2026.Shareholders adopted all proposals submitted to the meeting.The filing did no","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL48t40Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643059902","title":"NewcelX reports Stem Cell Reports study shows AstroRx cell therapy boosts remyelination in MS models","url":"https://stock-news.laohu8.com/highlight/detail?id=2643059902","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643059902?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:43","pubTimestamp":1781527382,"startTime":"0","endTime":"0","summary":"NewcelX announced publication of a peer-reviewed study evaluating AstroRx, an embryonic stem cell-derived astrocyte therapy, for multiple sclerosis.Results have already been presented via the Stem Cell Reports publication.The study found AstroRx supported repair processes tied to remyelination in lab work and an animal model, suggesting potential in chronic demyelinating diseases.The update extends evidence beyond a previously completed Phase 1/2a ALS trial, broadening the platform’s potential commercial scope.Management highlighted continued focus on advancing NCEL-101 for type 1 diabetes alongside development of additional stem-cell-derived assets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the or","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL9sWMP8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}